Last updated on March 2020

Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lymphoma | Central Nervous System Neoplasms | Non-Hodgkin's Lymphoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Histological diagnosis of PCNSL based on cytology/flow cytometry of cerebrospinal fluid (CSF) or brain biopsy
  • Written informed consent from patient or guardian
  • Immunocompetent

Exclusion Criteria:

  • Previous chemotherapy
  • Contra-indications for MRI (Pacemakers, defibrillators, aneurysm clips, any form of metal in the body, or severe claustrophobia)
  • Hypersensitivity to either 18F-Fluciclovine or 18F-FDG or to any of the excipients
  • Pregnancy (pregnancy test for all women in fertile age)
  • Breastfeeding
  • Weight > 120 kg
  • Estimated glomerular filtration rate (eGFR) <30ml/min/1,73m2
  • HIV-positive

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.